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Graft versus host disease (GVHD) is an uncommon complication after orthotopic liver transplantation (OLT) with an
incidence of 0.1–2%, but an 80–100% mortality rate. Patients can present with skin rashes, diarrhea, and bone
marrow aplasia between two to eight weeks after OLT. Diagnosis of GVHD is made based on clinical and histologic
evidence, supported by chimerism studies showing donor HLA alleles in the recipient bone marrow or blood.
Several therapeutic approaches have been used for the management of GVHD after OLT including increased
immunosuppression, decreased immunosuppression, and cellular therapies. However, success rates have been low,
and new approaches are needed.Introduction
The first successful human orthotopic liver transplant
(OLT) was performed in 1967 by a surgical team led
by Dr. Thomas Starzl in Denver, Colorado. Today
more than 6000 liver transplants are performed each
year in the United States with a one year survival rate
of 80–85% [1].
Acute graft versus host disease (GVHD), a frequent
complication after hematopoietic cell transplantation
(HCT), occurs infrequently after solid organ transplant-
ation [2]. However, GVHD has been reported following
blood transfusions [3], and any procedure that transfers
viable allogeneic lymphocytes into another individual
carries the potential risk of inducing GVHD. Thus,
among solid organ transplants GVHD is more likely in
recipients of liver or intestinal transplants where the
transplanted organs contain high numbers of donor lym-
phocytes [2]. After OLT the incidence of GVHD has
been estimated at 0.1–2%, but the mortality rate is 80–
100% [4,5]. Those estimates are derived from single in-
stitution studies; the United Network for Organ Sharing
(UNOS) in the United States does not routinely collect
information about GVHD, and the absence of registry
studies from other parts of the world suggests that this
complication is not routinely captured in databases.
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reproduction in any medium, provided the orwith GVHD after HCT. However, the likelihood of suc-
cess is low, and new approaches are needed.
Case presentation
A 53-year-old woman had a 14 year history of primary
biliary cirrhosis and received a liver transplant from a
cadaveric male donor. Transplantation was uncompli-
cated and she received 3 doses of rabbit antithymocyte
globulin (ATG) induction peritransplant. Post-transplant
immunosuppression was with tacrolimus and mycophe-
nolate mofetil. She was discharged from the hospital on
post-operative day (POD) 14. Prednisone 5 mg daily was
added on POD 20 for additional immunosuppression.
On POD 38 she was readmitted with tremors, forgetful-
ness, headache and difficulty with word finding. Her
absolute neutrophil count was 0.09 × 109/L. A bone mar-
row biopsy showed a markedly hypocellular marrow
with no evidence of dysplasia. Flow cytometry showed
less than 0.1% CD34 positive progenitors consistent with
severe myelosuppression. Bone marrow chimerism stud-
ies showed 80% liver donor and 20% host cells. Cytogen-
etic analysis was limited to one metaphase, which
showed a 46 XY karyotype, consistent with male donor
origin. Due to the pancytopenia and documented donor
chimerism, the working diagnosis was GVHD restricted
to the bone marrow. She had no nausea, diarrhea or skin
rash suggestive of gastrointestinal or skin GVHD, and
liver GVHD would not be expected given the OLT. She
was treated with rabbit anti-thymocyte globulin (ATG)
1.5 mg per kg for three consecutive days and alefaceptLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mus, mycophenolate mofetil and prednisone were dis-
continued. HLA-typing of her two siblings was initiated.
Follow-up bone marrow biopsy 12 days after adminis-
tration of ATG showed continued aplasia with < 0.1%
CD34+ cells. Bone marrow chimerism was 27% donor
and 73% host, while unsorted peripheral blood chimer-
ism showed 98% donor and 2% host cells. No further
bone marrow studies were done.
On POD 53 after OLT and day 7 after starting ATG,
she developed an erythematous, pruritic and painful skin
rash, most prominent on her hands but also extensively
involving her back, arms and legs. Skin biopsy was con-
sistent with GVHD, and chimerism studies showed male
(donor) lymphocytes in the biopsy specimen. She was
treated with topical steroids for these lesions given the
high risk of infection and the fact that the lesions were
not progressing.
Her subsequent clinical course was complicated by pro-
longed vancomycin-resistant enterococcal bacteremia,
which was treated with multiple antibiotics and granulo-
cyte transfusions. Weekly rituximab was administered for
EBV viremia and abdominal CT showing retroperitoneal
lymphadenopathy, suggestive of post-transplant lympho-
proliferative disorder.
Liver function tests were normal throughout her
course. HLA-typing showed that the liver donor shared
a single DQB1 antigen with the patient, but the donor
was heterozygous at all loci. Thus, the HLA typing of
donor and patient would not have predicted a high risk
for graft-versus-host disease.
Due to the profound bone marrow failure, the plan
was to proceed with allogeneic HCT. However, the
patient’s clinical condition deteriorated rapidly, and she
died POD 86 from septicemia, pulmonary aspergillosis
and respiratory distress syndrome before a donor was
identified.
The spectrum of clinical presentation
In 1988, Burdick and colleagues first described acute
GVHD after OLT, and more than 80 cases have been
reported since then [6]. Graft-versus-host disease after
OLT usually presents at two to eight weeks postopera-
tively with bone marrow aplasia, skin rash and diarrhea.
Liver function is not affected because the transplanted
liver lacks host antigen. The diagnosis may be delayed,
because similar presentations can be seen with drug
reactions and bacterial or viral infections. One of the
earliest clinical presentations is an erythematous macu-
lopapular skin rash. Detection of donor lymphocytes in
skin and a nonspecific lichenoid reaction pattern with
basal vacuolar changes, dyskeratosis and apoptotic cells
in the epidermis may be seen [7]. Donor cells are located
at the dermoepidermal junction and migrate upwardinto the epidermis; FISH for the Y chromosome may
confirm donor cells when donor and recipient are sex
mismatched [8,9].
Diarrhea is most commonly the result of absorptive
function loss caused by lymphocyte infiltration and de-
struction of the intestinal mucosa, and is more evident as
the post-transplant period lengthens. Biopsy specimens
of gastric, duodenal or colonic mucosa demonstrate
apoptosis and infiltration by donor lymphocytes [10]. In
case of pancytopenia, and suspected GVHD restricted to
the bone marrow, a bone marrow analysis usually shows
a markedly hypocellular marrow with no evidence of dys-
plasia. Flow cytometry is consistent with severe myelo-
suppression. Bone marrow chimerism studies show a
high percentage of liver donor and significantly less host
cells. Cytogenetic analysis is consistent with donor karyo-
type. Most patients die from infections, bone marrow
failure, gastrointestinal bleeding or multiorgan failure. As
with transfusion-associated GVHD, the high mortality
rate after OLT may explain why no clearly documented
cases of chronic GVHD have been reported.
Pathophysiology and diagnosis of GVHD
In OLT, about 109–1010 donor-derived leukocytes in-
cluding monocytes, T-cells and natural killer cells are
transplanted with the liver allograft [11], approximately
the same number as with a standard peripheral blood
stem cell infusion. This infusion of immunocompetent
cells and pluripotent progenitors, in conjunction with
the immunosuppression used for the liver transplant,
resembles the circumstances of an immunosuppressed
patient receiving a hematopoietic stem cell transplant.
In fact, donor lymphocytes can be routinely found
within three weeks and even up to 100 days after OLT
in the peripheral blood and bone marrow [12,13], and
detectable chimerism is associated with a decreased
risk of liver rejection. In most cases, over time the im-
mune system of the patient rejects the donor’s lym-
phocytes and full host chimerism is re-established.
Lymphocyte populations in the donor liver are distinct
from those in peripheral blood with a reversed ratio of
CD4:CD8 among hepatic lymphocytes and a higher
proportion of CD8+ cells and B lymphocytes [14].
Lymphocytes transferred with the donor’s liver may in-
duce severe pancytopenia by attacking and destroying
the recipient’s hematopoietic stem cells. Donor stem
cells with pluripotent function can migrate from the
liver to the recipient’s bone marrow, spleen, lymph
nodes and lungs and give rise to mature donor cells of
several hematopoietic lineages [15]. However, the num-
ber of hematopoietic stem cells transplanted with the
donor liver is not sufficient and the degree of HLA
mismatching is too great to allow engraftment and re-
constitution of the myeloid and erythroid lineages.
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upper and lower gastrointestinal involvement with nau-
sea, vomiting, and diarrhea, and skin involvement with
maculo-papular rashes and erythema. These clinical
signs and symptoms are identical to what is seen in
primary hematopoietic cell transplantation.
Engraftment of donor lymphocytes can be confirmed
by chimerism studies and identification of donor HLA
alleles in the recipient bone marrow or blood using a
polymerase chain reaction (PCR) test [16]. A DNA sam-
ple from the liver donor is required to confirm the
source of allogeneic cells. By convention the diagnosis of
donor engraftment is confirmed if the donor T-cell level
is >1% of T-cells detected. Persistently elevated levels of
donor CD8 + T/NK cells in the periphery (>10%) may
be indicative of GVHD. The level of donor CD8+ T and
NK cells may correlate with the severity of GVHD mani-
festations [17]. Early recognition and expeditious treat-
ment for GVHD is important to control the immune
reaction before it is too established and extensive organ
damage has occurred.
Domiati-Saad and colleagues reported serial single tan-
dem repeat results in 49 patients during the first two
months after OLT. In 38 of the 49 patients, donor T cell
chimerism was present on POD 2, and remained positive
by the end of the first week in 23 patients. Donor CD8+
T-cell chimerism was less than CD3+ T cell chimerism
measured on the same sample, but in the two patients
with acute GVHD the level of CD8+ T-cell chimerism
was generally equal to or greater than the CD3+ T-cell
chimerism. These two patients had characteristic signs
of acute GVHD. Donor CD3+ fractions above 10–20%
of lymphocytes correlated strongly with acute GVHD
[18].
Risk factors for GVHD
Shared HLA antigens between donor and recipient are
the most important risk factors for the induction of
GVHD. Use of an HLA-homozygous donor, resulting in
one way HLA matching in the GVHD direction, signifi-
cantly increases the risk of developing GVHD after OLT
[19].
Kamei and colleagues investigated the incidence of
fatal GVHD following living donor liver transplantation
(LDLT) in a retrospective study of 906 donor-recipient
pairs. They analyzed the ages of the recipient and donor,
donor relationship, original disease, initial symptoms,
onset and course of GVHD, Glucksberg stage, and
donor/recipient HLA type. Eight cases (1%) of fatal
GVHD after LDLT were identified with skin rash as the
most common initial manifestation. Seven cases had uni-
directional HLA matching at 3 loci (HLA-A, -B and –DR)
in the GVHD direction (donor homozygous). Case 8 had
unidirectional HLA matching at 2 loci (HLA-A and –DR)in the GVHD direction with the B locus matched because
of recipient homozygocity. Among these 8 cases, four
donors were children, three were parents and one was a
sibling. The authors suggested that the risk of fatal GVHD
following LDLT may depend on the number of loci with
donor-dominant one-way HLA matching, and was highest
with mismatching in the GVHD direction at all 3 loci
(HLA-A, -B and –DR) [20].
Key and colleagues reported a single-center analysis of
412 consecutive adult OLT recipients where HLA typing
data were available. Their data showed that HLA match-
ing at HLA-B, but not HLA-A or –DR was a significant
risk factor for the development of GVHD. Of 14 donor-
recipient pairs matched at HLA-B, three (21%) devel-
oped GVHD [21].
Chan and colleagues studied 205 OLT patients surviv-
ing more than 30 days. Four patients (2%) developed
GVHD, and three of them had received a donor liver
with steatosis graded mild or more severe. This analysis
did not identify HLA-matching as a risk factor for
GVHD, and could not confirm cryptogenic cirrhosis (as
an indication for liver transplantation) or older recipient
age (>40 yrs) to be predictors of GVHD. Alcoholic liver
disease, particularly in combination with hepatocellular
carcinoma and glucose intolerance, conferred a very high
risk for GVHD. They concluded that immunodeficient
states due to diabetes mellitus type I and II, various
autoimmune diseases and hepatocellular carcinoma
increased the risk for developing GVHD [22]. Infection
with CMV and HSV viruses can depress immunocompe-
tence and increase the risk for GVHD after OLT [23].
Although GVHD after OLT usually appears two to
eight weeks after OLT, similar to what is seen in
hematopoietic cell transplantation, Pollack et al reported
a case of a 52-year-old liver transplant recipient who
developed gastrointestinal symptoms and severe aplasia
8 months after OLT. After elimination of all other pos-
sible causes of these symptoms, chimerism analysis was
performed and showed that 96% of the peripheral blood
mononuclear cells were of liver-donor origin. An allogen-
eic peripheral blood HCT was carried out, but the pa-
tient died of septicemia 5 days after transplantation [24].
Severe aplastic anemia is a known late complication after
liver transplantation, sometimes occurring years after the
transplant [25-29]. Since chimerism studies were not per-
formed in the majority of these cases, it is possible that
GVHD could have been a contributing factor.
Treatment
Several therapeutic approaches have been proposed in
the literature. One strategy has been to decrease im-
munosuppression, in an effort to shift the balance in
favor of recipient immunity, but most investigators have
tried to increase immunosuppression.
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treated with corticosteroids as monotherapy because of
their well-known ability to induce apoptosis in lympho-
cytes and profound anti-inflammatory effect. However,
high doses of corticosteroids did not seem to improve
response rates and may increase the risk for these
patients to die of complications of GVHD, infection and
multi-organ failure due to side effects of high doses of
corticosteroids.
Treatment with immunosuppression beyond steroids
has been very heterogeneous and has included antimeta-
bolites, alkylating agents, anti-T cell antibodies, anti-B
cell antibodies, intravenous immunoglobulin, cytokine
inhibitors, immunostimulants and cellular therapy, in-
cluding T cell infusions and hematopoietic stem cell
transplantation.
The literature may reflect heavy publication bias, where
successful cases are reported, but unsuccessful treatment
attempts are not. In cases of GVHD-associated marrow
failure, standard treatments for GVHD have not been
successful.
The Table 1 summarizes the treatment approaches
that have been published, but outcome data are not pro-
vided, because many immunosuppressants were used in
combination, and no clear pattern of success or failure
emerged from reviewing the cases.
Anti-T cell antibodies have shown some success in
treating corticosteroid resistant GVHD, but are asso-
ciated with an increased risk for development of post-Table 1 Approaches used in the treatment of acute graft-





inhibitors (many), granulocyte colony
stimulating factors (many)
Antimetabolites Azathioprine [30]
Alkylating agents Cyclophosphamide [24]




Anti-B cell antibodies Rituximab [46,48]
Immunoglobulin Immunoglobulin [4,49,50]




Immunostimulants Thymosin alpha 1 [4,41]
Cellular therapy Ex vivo T cell expansion [47]
Hematopoietic cell transplantation [24,32,34]transplantation lymphoproliferative disease and viral re-
activation. Weekly monitoring by PCR for CMV and
EBV reactivation is recommended after starting antilym-
phocyte therapy.
The second most common approach is to administer
cytokine inhibitors, most commonly against IL2 and
TNF-α. Anti-interleukin-2 receptor antibodies daclizu-
mab and basiliximab have shown some benefits if intro-
duced early after high-dose corticosteroids. Infliximab is
a chimeric mouse/human immunoglobulin-G antibody
directed against soluble and transmembrane forms of
human TNF-α. Some authors suggest that infliximab
should be introduced earlier after the diagnosis of ster-
oid refractory acute GVHD, and if possible, before ATG
to avoid increased risks of infection and subsequent lym-
phoproliferative disorders [31]. Etanercept, a soluble
TNF-receptor, has been used successfully at the standard
dose of 25 mg twice a week for 8 weeks, although treat-
ment was complicated by invasive Aspergillus infection.
The authors recommended antifungal prophylaxis when
etanercept is used in acute GVHD because of its signifi-
cant rate of serious fungal complications [51]. The ex-
perience with HCT in cases of OLT-associated GVHD is
very limited.
There is one report of a haploidentical transplant for
GVHD-associated pancytopenia, with documented tran-
sient engraftment of the haploidentical donor cells fol-
lowed by rejection of the donor graft and recovery of
recipient hematopoiesis. The haploidentical donor was
related to the recipient (family member) and different
from the liver donor [32].
Another report showed successful harvest and ex vivo
expansion of recipient T cells, which upon re-infusion
were successful in combating GVHD [57]. Thus, allogen-
eic HCT could be a treatment for OLT-associated
GVHD, although the choice of conditioning regimens is
difficult in this complicated patient population. Although
the risk of GVHD after OLT is low, the high morbidity
and mortality of this complication demand efforts to pre-
vent it. Minimizing immunosuppression of the recipient
or decreasing the lymphocyte burden in the donor liver
might prevent GVHD but increase the rate of liver graft
rejection [58]. Depletion of T-lymphocytes from the liver
before transplantation could be achieved by treating the
cadaveric donor with ATG, but eliminating lymphocytes
from the liver may have an adverse effect on graft sur-
vival. Stable high donor chimerism has been associated
with tolerance to the donor liver [46,59]. Some patients
have been able to stop all immunosuppression after OLT;
hematopoietic chimerism was not tested in this study but
would be interesting to investigate [60]. Avoidance of
donors homozygous at HLA loci shared with a patient
would lower the risk of GVHD, but this information is
not typically available in a timely fashion when the
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transplant T cell depleting antibodies would help lower
GVHD, but might also increase the rate of liver rejection.
Conversely, increasing immunosuppression to try to pre-
vent GVHD or introducing agents more commonly used
for GVHD prophylaxis in hematopoietic cell transplant-
ation, such as methotrexate, just to prevent a complica-
tion seen in <2% of the population may not be
warranted, and could actually increase the rate of GVHD
if host immunity is more suppressed than donor
immunity.
It is clear that more successful approaches to treating
OLT GVHD need to be developed. Such advances will
require a coordinated effort among transplant centers to
systematically test potential treatment algorithms given
the rarity of this complication.
Summary
GVHD after OLT is a rare problem, but one associated
with a greater than 80% mortality. Rapid diagnosis, im-
munosuppressive treatment, and aggressive supportive
care are key to potentially reversing this otherwise fatal
condition. Our patient presented with symptoms five
weeks after OLT, which is similar to previously
reported cases. In cases of pancytopenia due to
GVHD, rapid evaluation for possible HCT may offer
the best option for survival. In conclusion, the diagno-
sis and treatment of GVHD after solid organ trans-
plantation is difficult because the early symptoms are
nonspecific, and no standard treatment is available. Re-
ducing the risk factors for development of GVHD,
identifying the disease promptly, preventing infection,
and starting treatment as early as possible may im-
prove the dismal outcome associated with this disease.
It would be helpful to report cases to registries and
world data banks that collect data from organ trans-
plant centers in order to better understand this com-
plication and allow for the design and testing of
treatments to try to improve survival.Competing interests
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